Dr. Jakob Dupont, Chief Medical Officer of OncoMed, commented, "The Wnt signaling pathway is implicated to be central to cancer stem cells survival and potentially a key therapeutic target in pancreatic cancer. Our Wnt pathway targeting antibody, vantictumab, reveals impressive preclinical data efficacy data in combination with gemcitabine and Abraxane in OncoMed's minimally passaged patient-derived pancreatic cancer models. We are pleased to have this Phase 1b trial underway and look forward to reporting data on the safety, efficacy and biomarker data of the vantictumab-Abraxane-gemcitabine combination in patients with late-stage pancreatic cancer."This is the third Phase 1b clinical study of vantictumab in combination with standard-of-care treatment initiated by OncoMed this year. Vantictumab plus docetaxel is being evaluated in non-small cell lung cancer and vantictumab combined paclitaxel is being studied in Her2-negative breast cancer. Interim results for the single-agent first-in-human Phase 1a trial for vantictumab in solid tumor patients were recently reported at the 2013 European Cancer Congress (ECC 2013) in Amsterdam, NL in September 2013. Results from the Phase 1a study showed that vantictumab is well tolerated with early evidence of single-agent activity. Additionally, clinical biomarker data from the Phase 1a trial indicating PD modulation of the Wnt pathway by vantictumab were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA in October 2013. "This pancreatic cancer trial is the third vantictumab Phase 1b study initiated by OncoMed this year as part of the clinical development program that we are advancing in partnership with Bayer," said Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed. "The clinical data from these three trials will yield important clinical information about this novel anti-cancer stem cell agent in the key solid tumor indications of non-small cell lung, breast and pancreatic cancer and may also lead to an opt-in decision by Bayer to take vantictumab into late-stage randomized clinical trials."